Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma

References

• Robak T, Korycka A, Kasznicki M, Wrzesień-Kuś A, Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 2005; 5: 424–444
   Web of Science ®Google Scholar
• Tallman M S, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–2474
   PubMed Web of Science ®Google Scholar
• Kay A C, Saven A, Carrera C J, Carson D A, Thurston D, Beutler E, et al. 2-chlorodeoxyadenosine treatment of low-grade non-Hodgkin's lymphomas. J Clin Oncol 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Betticher D C, von Rohr A, Ratschiller D, Schmitz S F, Egger T, Sonderegger T, et al. Fewer infections but maintained antitumor activity with lower-dose versus standard dose caldribine in pretreated low grade non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 850–859
   PubMed Web of Science ®Google Scholar
• Liliemark J, Porwit A, Juliusson G. Intermittent infusion cladribine (CdA) in previously treated patients with low-grade non-Hodkin's lymphoma. Leuk Lymphoma 1997; 25: 313–318
   PubMed Web of Science ®Google Scholar
• Robak T, Góra-Tybor J, Krykowski E, Walewski J A, Borawska A, Płużańska A, et al. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 26: 99–105
   PubMed Web of Science ®Google Scholar
• Tulpule A, Schiller G, Harvey-Buchanan L A, Lee M, Espina B M, Khan A U, et al. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer 1998; 83: 370–376
   Web of Science ®Google Scholar
• Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of Japanese phase II study. Int J Haematol 2004; 80: 267–277
   PubMed Web of Science ®Google Scholar
• Rummel M J, Chow K U, Jager E, Leimer L, Hossteld D K, Bergmann L, et al. Intermittent 2-hour infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma 1999; 82: 957–964
   Google Scholar
• Rummel M J, Chow K U, Jager E, Hossfeld D K, Bergmann L, Peters H D, et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol 1999; 10: 115–117
   PubMed Web of Science ®Google Scholar
• Kong L R, Huang C F, Hakimian D, Variakojis D, Klein L, Kuzel T M, et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced indolent non-Hodgkin's lymphoma. Cancer 1998; 82: 957–964
   PubMed Web of Science ®Google Scholar
• Saven A, Emanuele S, Kosty M, Kozioł J, Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with utreated indolent non-Hodgkin's lymphoma. Blood 1995; 86: 1710–1716
   PubMed Web of Science ®Google Scholar
• Fridrik M, Jager G, Kienzer H R, Hausmaninger H, Oppitz P, Krieger O, et al. Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine) – 2 h infusion for 5 days – as first-line treatment for advanced low-grade non-Hodgkin's lymphoma. Eur J Cancer 1998; 34: 1560–1564
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff J M, et al. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine. Leukemia 1999; 13: 918–925
   PubMed Web of Science ®Google Scholar
• Góra-Tybor J, Robak T. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemia L1210 and P388. Acta Haematol Pol 1993; 24: 177–182
   PubMedGoogle Scholar
• Hoffman M, Xu J C, Lesser M, Rai K. Cytotoxicity of 2-chlorodeoxyadeosine (cladribine – 2-CdA) in combination with other chemotherapy drugs against two lymphoma cell lines. Leuk Lymphoma 1999; 33: 141–145
   PubMed Web of Science ®Google Scholar
• Szmigielska-Kapłon A, Ciesielska E, Smigiero L, Robak T. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002; 68: 370–375
   PubMed Web of Science ®Google Scholar
• Laurencet F M, Ballabeni P, Rufener B, Hess U, Cerny T, Fey M, et al. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta Haematol 2007; 117: 40–47
   PubMed Web of Science ®Google Scholar
• Van den Neste E, Louviaux I, Michaux J L, Delnnoy A, Michaux L, Sonet A, et al. Phase I/II study of 2-chloro-2-deoxyadenosine with cyclophosphamide in patients with pretreated B-cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 2000; 14: 1136–1142
   PubMed Web of Science ®Google Scholar
• Kalinka E, Wajs J J, Sułek K S, Blasińska-Morawiec M, Centkowski P, Ceglarek B, et al. Randomized comparison of cladribine single (C) or in combination with cyclophosphamide (CC) and COP in previously untreated low-grade B-cell non-Hodgkin lymphoma patients. Blood 2006; 108(Suppl 1)703a, (abstract 2481)
   Google Scholar
• Robak T, Góra-Tybor J, Urbańska-Ryś H, Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low-grade non Hodgkin's lymphoma. Leuk Lymphoma 1999; 32: 359–368
   PubMed Web of Science ®Google Scholar
• Armitage J O, Tobinai K, Hoelzer D, Rummel M J. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int J Hematol 2004; 79: 311–321
   PubMed Web of Science ®Google Scholar
• Rummel M J, Chow K U, Karakas T, Jager E, Mezger J, von Grunhagen U, et al. Reduced dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002; 38: 1739–1746
   PubMed Web of Science ®Google Scholar
• Robak T, Góra-Tybor J, Chojnowski K. Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low grade lymphoid malignancies. Haematologica 2000; 85: 215–216
   PubMed Web of Science ®Google Scholar
• Robak T, Błoński J Z, Kasznicki M, Góra-Tybor J, Dwilewicz-Trojaczek J, Boguradzki P, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia 2001; 15: 1510–1516
   PubMed Web of Science ®Google Scholar
• Robak T, Błoński J Z, Góra-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter randomized trial of the Polish Adults Leukemia Group (PALG CLL 2). Blood 2006; 108: 473–479
   PubMed Web of Science ®Google Scholar
• Robak T, Góra-Tybor J, Lech-Marańda E, Błoński J Z, Kasznicki M. Cladribine in combination with mitoxantrone and cyclophsophamide (CMC) in the treatment of heavily pretreated patients with advanced indolent lymphoid malignancies. Eur J Haematol 2000; 66: 188–194
   Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M S, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Duffy D R, Santner T J. Confidence intervals binomial parameter based on multistage tests. Biometrics 1987; 47: 207–214
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Cohen B J, Moskowitz C, Straus D, Noy A, Mednick E, Zelenetz A. Cyclophosphamide fludarabine (CCF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42: 1015–1022
   PubMed Web of Science ®Google Scholar
• Thomas D W, Owen R G, Johnson S AN, Hillmen P, Seymour J F, Wolf M M, Rule S AJ. Superior quality and duration of response among patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005; 46: 549–552
   PubMed Web of Science ®Google Scholar
• Forspointer R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Bloński J Z. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107: 1542–1550
   PubMed Web of Science ®Google Scholar
• Robak T. Rituximab plus purine nucleoside analogs in the treatment of indolent lymphoid malignancies. Am J Cancer 2005; 4: 279–292
   Google Scholar
• Forspointner R, Unterhalt M, Dreyling M, Bock H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphmide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• Redman J R, Cabanillas F, Velasquez W S, Mc Laughlin P, Hagemeister F B, Swan F, Jr, et al. Phase II trial of fludarabine phosphate in lymphoma an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Child J A, Johnson S A, Rule S, Smith G M, Morgan G J, Johnson P W, et al. FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37: 309–317
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kotani T, Nkamura Y, Ueda M. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. Int J Hematol 2006; 83: 450–453
   PubMed Web of Science ®Google Scholar
• Villanueva M L, Vose J M. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2006; 4: 521–530
   PubMedGoogle Scholar
• Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006; 20: 235–244
   PubMed Web of Science ®Google Scholar
• Laudi N, Arora M, Burns L, McGlave P, Miller J, Bohac G, et al. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am J Hematol 2006; 81: 519–524
   PubMed Web of Science ®Google Scholar